Analyst Price Targets — GUTS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 29, 2026 9:20 pm | — | Morgan Stanley | $2.00 | $0.58 | TheFly | Fractyl Health downgraded to Equal Weight from Overweight at Morgan Stanley |
| December 19, 2025 11:17 am | Whitney Ijem | Canaccord Genuity | $8.00 | $2.26 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on Fractyl Health Inc (GUTS) |
Latest News for GUTS
GUTS' shares surge after Revita patients retain up to 84% of GLP-1-induced weight loss in a year, compared with 46% for sham patients.
Fractyl Health, Inc. (GUTS) Discusses 1-Year REMAIN-1 Data Demonstrating Durable Weight Maintenance After GLP-1 Discontinuation Transcript
Fractyl Health Inc. (NASDAQ:GUTS) reported Wednesday one-year results from the Midpoint Cohort of its REMAIN-1 study, saying a single treatment with its investigational Revita DMR System helped patients maintain more of their GLP-1-induced weight loss than a sham procedure.
Fractyl Health NASDAQ: GUTS reported one-year data from the randomized midpoint cohort of its REMAIN-1 study, saying its Revita procedure helped patients maintain a larger share of GLP-1-induced weight loss after discontinuing GLP-1 therapy compared with a sham procedure.
Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations Next anticipated Revita® milestones are topline six-month randomized data from the REMAIN-1 Pivotal Cohort in early Q4 2026 and a potential FDA De Novo marketing application submission in late Q4 2026 Company to host investor webcast today at 8:00 a.m. ET BURLINGTON, Mass.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GUTS.
U.S. House Trading
No House trades found for GUTS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.